Month: December 2015

15
Dec 2015

Bionest

Visit Us at the JP Morgan Healthcare Conference – Jan 11-14 in San Francisco!

We are looking forward to attending the JP Morgan Healthcare Conference again January 11-14, 2016, in San Francisco.   Three of Bionest’s leaders, Alain J. Gilbert, Olivier Lesueur, and Bob Easton, will be available to meet one-on-one for 30 minutes in our private suite, between Monday Jan 11 and Thursday Jan 14.   For Bionest,...
10
Dec 2015

Bionest

ASH News on CAR-T Therapies Reinforces Previous Enthusiasm for the Approach… But Challenges Remain

  CAR-T therapies involve removing T cells from individual patients and engineering them to recognize and destroy that patient’s cancer. Early clinical results over the last few years raised considerable interest in this cell-based immunotherapeutic approach, and now that several hundred patients have been treated, the enthusiasm may be justified. New data presented this week...
9
Dec 2015

Bionest

BIO Europe 2015 Conference – Reflections

Bionest attended BIO Europe in Munich last month and witnessed firsthand the flurry of deal making activity.  In many ways 2015 has been a landmark year for deal making.  Companies big and small have made headlines, striking deals across every corner of the industry and for myriad reasons ranging from combination collaborations to the recent...
9
Dec 2015

Bionest

Promise of Immunotherapy Featured on Today Show

The recent news of Jimmy Carter’s excellent response to cancer immunotherapy — he reported earlier this week that his brain cancer appears to be gone following treatment with Keytruda — was highlighted this morning on the  Today Show.  The field of immunotherapy – an approach that leverages the body’s own immune system to treat disease...
2
Dec 2015

Bionest

Data Is Key to Forming Immunotherapy Partnerships

We were pleased to participate in a “State of the Industry” panel on immuno-oncology at the 2015 BIO Investor Forum in October. The lively discussion included other participants from across the industry and investing world, including the licensing office of Merck & Co. and Baxter’s corporate venture arm, Baxalta, as well as small biotech company...